Pittsburgh, PA, United States of America

Dave Gingrich

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Dave Gingrich

Introduction

Dave Gingrich is an accomplished inventor based in Pittsburgh, PA, known for his significant contributions to cancer treatment methodologies. With a focus on individualizing chemotherapy, his work aims to enhance patient outcomes through innovative approaches.

Latest Patents

Dave Gingrich holds a patent for "Methods for selecting active agents for cancer treatment." This invention provides methods for individualizing chemotherapy, particularly neoadjuvant chemotherapy. It includes techniques for predicting a cancer patient's response to treatment by assessing the probability of a positive response to candidate agents prior to surgery. The invention involves culturing malignant cells from a patient's biopsy specimen and testing these cells for resistance or sensitivity to various candidate agents. Additionally, it offers methods for accurately scoring and interpreting assay results, which can predict a patient's pathological complete response upon receiving the corresponding treatment regimen.

Career Highlights

Gingrich is currently associated with Precision Therapeutics, Inc., where he continues to develop innovative solutions in cancer treatment. His work is pivotal in advancing personalized medicine, particularly in the field of oncology.

Collaborations

Dave collaborates with notable colleagues, including Zhibao Mi and Mike Gabrin, who contribute to the research and development efforts at Precision Therapeutics, Inc.

Conclusion

Dave Gingrich's innovative work in cancer treatment exemplifies the potential of personalized medicine to improve patient care. His contributions through patented methodologies are paving the way for more effective chemotherapy options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…